Kintor Pharma Reports the Completion of Patient Enrollment in P-II Clinical Trial of KX-826 for Female Patients with Androgenetic Alopecia
Shots:
- The company has completed the patient enrollment in the P-II trial to evaluate the efficacy & safety of KX-826 in 160 patients with female AGA
- The 1EPs of the trial is the change from baseline in non-vellus TAHC @24wk. On Sept 8, 2021, the P-II trial met the1EPs of KX-826 on adult male patients which demonstrated a good efficacy and safety profile
- KX-826 is an AR antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris & is currently being evaluated in a P-III clinical trial in China and a P-II trial in the US for male AGA patients. The company is conducting a P-II clinical trial of KX-826 in China for the treatment of acne vulgaris
Ref: PR Newswire | Image: Kintor
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
